Ivan Borrello, M.D., joined Gamida Cell’s Board of Directors in June 2022. Dr. Borrello is the medical director of the Myeloma, Bone Marrow Transplant and Cell Therapies program at the Tampa General Hospital Cancer Institute. Prior to that, Dr. Borrello served as director of the Cellular Therapeutics and Multiple Myeloma programs at The Johns Hopkins Hospital, where he also worked as an attending physician. Dr. Borrello was also previously associate professor of oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine from 2008 to 2022.
Dr. Borrello is a co-founder of WindMIL Therapeutics, where he has served as senior clinical advisor since 2014, and is a co-founder of Meridian Therapeutics, where he has served as senior clinical advisor since 2021. From 2001 to 2008, he was an Assistant Professor of Immunotherapy and Hematopoiesis, Hematologic Malignancies at Johns Hopkins Oncology Center. Dr. He did his Fellowship in Oncology at Johns Hopkins University and completed his Residency in Internal Medicine at the University of Chicago. Borrello received an M.D. from the Medical College of Virginia and a B.A. in Biology from Catholic University.